Florida is currently home to 3759 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
NCT06643377
Recruiting
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic (PK) study). Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment (mea... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/17/2025
Locations: Velocity Clinical Research, New Smyrna Beach ( Site 0003), Edgewater, Florida
Conditions: Healthy, Renal Impairment
Register for Updates
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
NCT06602141
Recruiting
The purpose of this research study is to study the effects of endurance exercise training on adipose (fat) tissue quality and insulin sensitivity in men and women.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/17/2025
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Obesity
Register for Updates
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
Recruiting
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Advanced Urology Institute (Solaris), Largo, Florida
Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
Register for Updates
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/17/2025
Locations: Aqualine Clinical Research, Naples, Florida
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study of Obexelimab in Patients with Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Clinical Research of West Florida, Inc, Clearwater, Florida
Conditions: Systemic Lupus Erythematosus
Register for Updates
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
NCT06525077
Recruiting
This is a double-blind, placebo-controlled, randomized withdrawal, multicenter study of the efficacy and safety of FT218. FT218 drug product is a once-nightly formulation of sodium oxybate for extended-release oral suspension. The study will enroll subjects who are diagnosed with idiopathic hypersomnia. Subjects will be eligible to enroll regardless of current treatment with oxybate therapy or stimulants/alerting agents at study entry. The estimated total duration of study for each subject is ap... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/17/2025
Locations: Florida Pediatric Institute, Winter Park, Florida
Conditions: Idiopathic Hypersomnia
Register for Updates
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Recruiting
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded ind... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751
Recruiting
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Research Site, Hollywood, Florida
Conditions: Advanced Breast Cancer
Register for Updates
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Neoclinical Research, Hialeah, Florida
Conditions: Severe Hypertriglyceridemia
Register for Updates
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
NCT06168409
Recruiting
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/17/2025
Locations: Research Site, Hollywood, Florida
Conditions: Resistant Hypertension
Register for Updates
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
NCT06088290
Recruiting
The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Leiomyosarcoma
Register for Updates
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
NCT05956626
Recruiting
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
03/17/2025
Locations: Bascom Palmer Eye Institute, Miami, Florida
Conditions: Stargardt Disease
Register for Updates